Yes!  It does looks promising!

Here is everything I have on apabetalone for 'Colorectal Cancer': 

https://www.nature.com/articles/s41416-021-01321-0

https://www.mdpi.com/1422-0067/22/7/3352/htm(HDL angle)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166002/

https://www.ncbi.nlm.nih.gov/pubmed/30098223

https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12367

https://www.mdpi.com/2072-6694/11/8/1097/htm

A recent study showed that human colon adenocarcinoma (CA) cells stably transfected with ABCA1, exhibit increased proliferative, invasive and migratory behavior, which could be inhibited by simultaneous, transgenic overexpression of ApoA-I, or by exogenous treatment with human recombinant ApoA-I [157]. This inhibition was associated with downregulation of cyclooxygenase 2 (COX-2), a known promoter of colon adenocarcinoma involved in proinflammatory processes. In the same study, apabetalone, a small molecule BET-inhibitor, used in experimental therapeutics of atherosclerosis and known to induce production of ApoA-I, reduced the ABCA1-driven proliferative and invasive behavior of CA cells [157]. Another study showed that treatment of CA cells with the ApoA-I-mimetic peptide L-4F induced G0/1 cell cycle arrest, associated with decreased expression levels of cyclins D1 and A and decreased cell viability [158]. Also, it reduced the survival of CA cells stimulated by lysophosphatidic acid (LPA), a potent bioactive phospholipid, known to decrease its free concentration in the cell culture media [158]. 

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/712700-abca1-overexpression-worsens-colorectal-cancer-prognosis-and-this-can-be-ameliorated-by-apabetalone/messages/2202805#message

This is a Spanish study in which the authors propose that the upregulation of ApoA-1 by apabetalone is reponsible for reduced malignancy in colorectal cancer cells. 

"Based on these results, we propose here, for the first time, the potential use of apabetalone, a stimulator of APOA1 so far only considered for CVD, as a bona fide inhibitor of colorectal cancer invasiveness."

https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12367